WuXi Biologics (Cayman) Inc. (WXXWY)
OTCMKTS · Delayed Price · Currency is USD
8.42
-0.30 (-3.44%)
At close: Dec 26, 2025
WuXi Biologics Revenue
WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.
Revenue (ttm)
20.05B CNY
Revenue Growth
+17.16%
P/S Ratio
6.18
Revenue / Employee
1.59M CNY
Employees
12,575
Market Cap
17.31B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
WuXi Biologics News
- 3 days ago - WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure - PRNewsWire
- 8 days ago - WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security - PRNewsWire
- 25 days ago - WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority - PRNewsWire
- 25 days ago - WuXi Biologics Signs MoU With Qatar Free Zones Authority To Set Up Middle East CRDMO Center - Nasdaq
- 2 months ago - WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index - PRNewsWire
- 2 months ago - WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan - PRNewsWire
- 2 months ago - WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year - PRNewsWire
- 3 months ago - WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™,to Accelerate Biologics Development with High Titer and Superior Stability - PRNewsWire